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Splanchnic Clearance and Its Relationship
with Drug Elimination by the Liver and
Gastrointestinal Tract
To the Editor:
Organ clearances are considered to be additive terms,
yet this is not always the case. For example, splanchnic
clearance is not simply the sum of hepatic and gastrointes-
tinal clearances. Due to the anatomy and arrangement of
blood flow within this region, splanchnic extraction and
clearance are, instead, complex and hybrid terms. As such,
a kinetic model was developed by Pang and Gillette1 and
subsequently reported by Lin et al.2 describing the disposi-
tion of intravenously administered drugs that undergo both
intestinal and hepatic metabolism. Thus, CLspl ) CLH +
FHCLGI, in which CLspl is the splanchnic clearance, CLH is
the hepatic clearance, FH is the fraction of drug escaping
extraction on each pass through the liver, and CLGI is the
gastrointestinal clearance.
The splanchnic clearance equation is consistent with the
contributions of hepatic and gastrointestinal elimination
at their limits. As a result, if clearance by the gastrointes-
tinal tract is absent (i.e., CLGI ) 0), then splanchnic
clearance is simply equal to the hepatic clearance alone
(i.e., CLspl ) CLH). Further, if clearance by the liver is
absent (i.e., CLH ) 0 and FH ) 1), then splanchnic clearance
is simply equal to the gastrointestinal clearance alone (i.e.,
CLspl ) CLGI). However, when hepatic and gastrointestinal
elimination are both operative, it is very difficult to predict
the overall effect on CLspl because of the parallel as well
as sequential perfusion of these two organs. This relation-
ship is further complicated by concentration- or dose-
dependent kinetics that may effect changes in clearance
and/or extraction. To illustrate this point, we have exam-
ined this relationship in dogs using direct in vivo measure-
ments of 5-fluorouracil (FUra) clearance by the liver,
gastrointestinal tract, and splanchnic region. The surgical
procedure, experimental methods, and results concerning
the regional pharmacokinetics of FUra have been published
elsewhere.3
Following intravenous infusions of FUra at five sequen-
tially escalated dose rates (0.0625, 0.250, 0.750, 1.50 and
2.00 µmol/min/kg), values for CLH (11.7, 11.8, 11.2, 11.0,
and 9.88 mL/min/kg), FH (0.225, 0.229, 0.298, 0.320, and
0.398), CLGI (7.90, 7.26, 5.42, 4.98 and 3.42 mL/min/kg) and
CLspl (13.5, 13.5, 12.8, 12.6 and 11.2 mL/min/kg) were
reported, respectively. At the extremes of dose-rate (i.e.,
0.0625 vs 2.00 µmol/min/kg), a substantial 57% reduction
occurred in gastrointestinal clearance while a modest 16%
reduction occurred in hepatic clearance. On the basis of
these changes, one might be inclined to believe that
splanchnic clearance would also decline to a large extent.
However, the fraction escaping extraction by the liver was
increased by a substantial 77%, thus attenuating the effect
of a reduced gastrointestinal clearance. As a result, the
overall splanchnic clearance of FUra was reduced by only
17% at the larger dose-rate. A final observation was that
hepatic clearance assumed the major contribution to FUra’s
splanchnic clearance, regardless of dose-rate. Over the 32-
fold range of dose-rates studied, clearance by the liver
accounted for about 87% of drug elimination by the
splanchnic region as a whole. Although this observation
was specific for FUra, similar results would be predicted
for other high hepatic extraction drugs because small
values for hepatic availability (FH e 0.3) would minimize
the role of the gastrointestinal tract in systemic drug
elimination.
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